Global RNA Therapeutics Market Size, Share And Forecast To 2034

The Global RNA Therapeutics Market was estimated at USD 20.32 billion in 2025 and is anticipated to grow to USD 45.35 billion by 2034, growing at a CAGR of 9.37% from 2026-2034.

The market growth is primarily attributed to the emergence of next-generation RNA platforms, a surge in approvals of RNAi therapies, and the rapid adoption of personalized RNA therapies for rare and genetic diseases.

Market Dynamics Advancements in RNA delivery technologies

The advancements in RNA delivery technologies have increased their adoption across various therapeutic areas due to their safe and highly effective mechanisms.

• For instance, new delivery methods such as exosomes and peptide based carriers are delivering RNA treatments such as recently approved Alnylam's Givlaari and Amvuttra to highly complicated tissue structures in neurological and cancer conditions.

This trend is expected to boost the demand for recently approved RNA therapeutics, which, in turn, propels the market growth.

The accelerated growth in the development of new mRNA drugs by biopharma companies for cancer, genetic diseases, and cardiovascular conditions is attracting new investments and creating new opportunities for market growth.

• For instance, Moderna Inc., a leading mRNA vaccine developer, has 28 vaccine candidates under clinical trials for the treatment of viral diseases.

Therefore, strong clinical pipelines are expected to boost the research and adoption of new mRNA vaccines during the forecast period.

Key Highlights

• By type, the market is segmented into mRNA therapeutics, RNA interference (RNAi), antisense oligonucleotides, and others. The RNA interference (RNAi)segment is expected to register the fastest CAGR of 9.74% in 2026-2034. This growth is attributed to the expanding therapeutic approvals and advancements in delivery technologies.
• By application, the market is categorized into oncology, infectious diseases, genetic diseases, ophthalmology, cardiovascular diseases, and others. The oncology segment is estimated to grow at the fastest pace with a CAGR of 10.27%, owing to high medical needs for RNA therapeutics in this disease area, advancements in the immune oncology platform, and strong R&D partnerships.
• On the basis of end user, the market is divided into hospitals & clinics, research institutes, and others. The hospitals & clinics segment dominated the market in 2025 and is estimated to grow at the fastest CAGR, owing to the increasing availability of marketed RNA drugs through hospital settings, expanding vaccine programs, and the establishment of specialty clinics for rare and oncology diseases.
• Asia Pacific is estimated to be the fastest-growing region in the global market, with a CAGR of 11.64%. This growth is attributed to expanding biopharmaceutical research, a surge in funding initiatives, and the expansion of clinical trial activities.